Susquehanna Fundamental Investments’s Akebia Therapeutics AKBA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-77,278	Closed	-$24K	–	1181
2022 Q3	$24K	Buy	+77,278	New	+$30.3K	﹤0.01%	1398
2022 Q1	$222K	Hold	309,569	–	–	﹤0.01%	1334
2021 Q4	$700K	Buy	309,569 +273,049	+748%	+$745K	0.02%	792
2021 Q3	$105K	Sell	36,520 -36,080	-50%	-$103K	﹤0.01%	1616
2021 Q2	$275K	Sell	72,600 -148,025	-67%	-$498K	0.01%	1395
2021 Q1	$747K	Buy	+220,625	New	+$795K	0.01%	997

Other funds holding AKBA

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OCM

Ovata Capital Management Hong Kong $1.33B AUM 5.69% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Susquehanna Fundamental Investments's AKBA Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Akebia Therapeutics (AKBA) in Q4 2022, closing a stake of 77,278 shares — an estimated $24K sold.

Susquehanna Fundamental Investments first reported a position in AKBA in Q1 2021 and held it in 6 quarters. The position peaked at $747K in Q1 2021. 75 funds tracked by Wall St. Rank hold AKBA as of Q4 2022.

Susquehanna Fundamental Investments reported no remaining Akebia Therapeutics position as of Q4 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 77,278 Akebia Therapeutics shares in Q4 2022, an estimated $24K.
Susquehanna Fundamental Investments first reported a position in Akebia Therapeutics in Q1 2021 and held it in 6 quarters.
Susquehanna Fundamental Investments's Akebia Therapeutics position peaked at $747K in Q1 2021.
75 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.